Table 1.

Examples of the approved nanomedicines.

Trade Name	Active Ingredient	Nanoformulation	Indications	Approval Date	Clinical Effect	Reference
Doxil®	Doxorubicin	Liposome	Ovarian and breast cancer	1995	Fewer and less severe side effects Longer periods of drug circulation in vivo Prolonged interval to progression and progression-free survival time	[32]
DaunoXome®	Daunorubicin	Liposome	HIV-related Kaposi’s Sarcoma	1996	No obvious cardiotoxicity Longer periods of drug circulation in vivo As effective as the conventional chemotherapy	[33]
DepoCyt®	Cytarabine	Liposome	Lymphomatous meningitis	1999	Reduced cardiotoxicity Pronounced effectiveness	[34]
Eligard®	Leuprolide	Nanosphere	Prostate cancer	2002	More sustained testosterone suppression Higher response rates	[35]
Lipusu®	Paclitaxel	Liposome	Ovarian cancer and breast cancer	2003	Reduced adverse reactions As effective as the paclitaxel	[36]
Abraxane®	Paclitaxel	Nanoparticle	Metastatic breast cancer	2005	Lower overall toxicity Better anticancer effect	[37]
Genexol-PM®	Paclitaxel	Micelle	Breast cancer and Lung cancer	2007	Reduced toxicities of paclitaxel Enhanced antitumor efficiency	[38]
Marqibo®	Vincristine	Liposome	Acute lymphoid leukemia	2012	Reduced neurotoxicity Overall increase in therapeutic index	[39]
Onivyde®	Irinotecan	Liposome	Metastatic pancreatic cancer	2015	Longer half-life Enhanced anticancer efficiency	[40]
Liporaxel®	Paclitaxel	Emulsion	Gastric cancer	2016	Reduced neurotoxicity As effective as paclitaxel	[41]
Vyxeos®	Daunorubicin and cytarabine	Liposome	Acute myeloid leukemia	2017	Prolonged overall survival (OS) and event-free survival (EFS)	[42]